Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Daily aspirin use may prevent fibrosis progression in nonalcoholic fatty liver disease

08 Jun 2019

Use of aspirin on a daily basis appears to be associated with less severe histologic features of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), as well as reduce the risk of progression to advanced fibrosis with time, a study has found.

Researchers examined 361 adults with biopsy-confirmed NAFLD every 3–12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score and aspartate aminotransferase to platelet ratio indices). Liver biopsies were collected at baseline for histologic analyses.

At baseline, 151 patients reported daily aspirin use. Compared with nonregular users, daily users had a significantly lower likelihood of NASH (adjusted odds ratio [aOR], 0.68, 95 percent CI, 0.37–0.89) and fibrosis (aOR, 0.54, 0.31–0.82).

In the group of patients with baseline F0-F2 fibrosis (n=317), 86 developed advanced fibrosis over 3,692 person-years. Daily aspirin use was associated with a significantly lower risk of developing incident advanced fibrosis compared with nonregular users (adjusted hazard ratio [aHR], 0.63, 0.43–0.85).

The relationship between fibrosis progression and aspirin use was dependent of duration of use (p-trend=0.026), with the greatest benefit found in daily aspirin users for 4 years (aHR, 0.50, 0.35–0.73).

In contrast, use of nonaspirin nonsteroidal anti-inflammatory drugs was not associated with the risk of advanced fibrosis (aHR, 0.93, 0.81–1.05).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.